Donepezil Hydrochloride
Product Images NDC 63304-129

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 63304-129). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ranbaxy Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mglabel (10mglabel)

Label of Donepezil Hydrochloride Tablets USP 10 mg by Ranbaxy Pharmaceuticals Inc. The label states 'Rx only' and '30 Tablets.' It includes a caution about inspecting the patient package insert and storage instructions, along with two barcodes and spaces for lot and expiration dates.*

FDA Label Image

5mglabel (5mglabel)

Donepezil Hydrochloride Tablets, USP 5 mg bottle label from Ranbaxy Pharmaceuticals Inc. The label indicates a 30-tablet quantity, prescription-only status, and includes directions about dispensing with a Medication Guide. It also provides storage instructions (20°-25°C) and warnings about light-sensitive blisters. The label shows NDC 63304-128-30 and contains various barcodes and lot/expiration date fields.*

FDA Label Image

Graph01 (Graph01)

A line graph comparing the ADAS-cog change from baseline over 30 weeks of drug treatment for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis shows cognitive change scores with clinical improvement upward and decline downward; the x-axis shows weeks of treatment. Both Donepezil doses show less cognitive decline compared to placebo over time.*

FDA Label Image

Graph02 (Graph02)

A cumulative percentage of patients graph illustrating changes in ADAS-cog scores from baseline. The x-axis shows change from baseline, while the y-axis shows cumulative percentage of patients. The plot compares Placebo, Donepezil Hydrochloride 5 mg, and 10 mg dosage groups with markers and curves, alongside a table summarizing percent changes for each treatment group at various change points.*

FDA Label Image

Graph03 (Graph03)

Bar graph depicting the distribution of CIBIC-plus ratings among patients treated with Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis shows ratings from markedly improved to markedly worse, and the y-axis shows the percentage of patients. Data separates patient outcomes by treatment and placebo groups.*

FDA Label Image

Graph04 (Graph04)

A line graph showing the mean change from baseline in ADAS-cog scores over weeks of drug treatment for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The y-axis represents clinical improvement or decline, while the x-axis shows weeks of drug treatment up to 12 weeks and a placebo period. Donepezil groups show greater clinical improvement compared to placebo.*

FDA Label Image

Graph05 (Graph05)

A cumulative percentage graph depicting the change from baseline in ADAS-cog scores for three treatment groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. The x-axis shows change from baseline, and the y-axis shows cumulative percentage of patients. The graph includes labeled points corresponding to 7 points, 4 points improvement, and no change, with a data table summarizing treatment group percentages at specific ADAS-cog score changes.*

FDA Label Image

Graph06 (Graph06)

A bar graph comparing the percentage of patients by CIBIC-plus rating for Donepezil Hydrochloride at 10 mg/day, 5 mg/day, and placebo groups. The ratings range from markedly improved to markedly worse, with values shown along the Y-axis representing patient percentages. The graph includes a legend differentiating the three groups by black, gray, and white bars respectively.*

FDA Label Image

Graph07 (Graph07)

A line graph showing SIB (Severe Impairment Battery) score changes from baseline over 6 months of treatment, comparing Donepezil Hydrochloride 10 mg/day and placebo. The vertical axis measures mean change from baseline with error bars, while the horizontal axis shows months of drug treatment. The graph indicates clinical improvement and decline directions, with Donepezil Hydrochloride demonstrating improvement and placebo showing decline over time.*

FDA Label Image

Graph08 (Graph08)

A cumulative percentage of patients graph comparing Donepezil Hydrochloride 10 mg/day with placebo. The x-axis represents SIB (Severe Impairment Battery) change from baseline, and the y-axis shows the cumulative percentage of patients. The data points illustrate differences in patient response between the Donepezil Hydrochloride treatment and placebo groups.*

FDA Label Image

Graph09 (Graph09)

A line graph showing the ADCS-ADL change from baseline over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The y-axis measures change from baseline with clinical improvement upward and clinical decline downward. Donepezil shows less decline compared to placebo over time.*

FDA Label Image

Graph10 (Graph10)

A line graph comparing cumulative percentage of patients for Donepezil Hydrochloride 10 mg/day versus placebo, plotted against ADCS-ADL change from baseline. The x-axis shows changes from baseline, and the y-axis shows cumulative percentage of patients, illustrating patient response distributions for both treatment groups.*

FDA Label Image

Structure (Structure)

Chemical structure of Donepezil Hydrochloride shown as a molecular diagram with labeled rings and functional groups, including methoxy groups, piperidine ring, and benzyl moiety, paired with an HCl component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.